Epicrispr Biotechnologies to Begin Clinical Trials for its Lead Epigenetic Therapy for FSHD Patients
The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.
SRTX has been attempting to raise fresh financing needed to fund its near-term working capital requirements and stretch its ...
A Peninsula biotech company raised $68 million from investors — including a venture philanthropy fund started by Lululemon ...
The startup is using CRISPR tools to stop errant expression of a gene linked to facioscapulohumeral muscular dystrophy, a disorder on the radars of several drugmakers.
SOLVE FSHD Announces Strategic Collaboration with Transcripta Bio to Advance Drug Discovery for FSHD
Under this agreement, SOLVE FSHD will provide strategic funding to support a drug screening initiative led by Transcripta Bio. The project will analyze a broad range of approved and late-stage ...
Investors welcomed reports that the next wave of President Trump's tariffs will be more targeted than threatened.
Investors welcomed reports that the next wave of President Trump's tariffs will be more targeted than threatened.
Intel on Wednesday (Mar 12) named former board member and chip industry veteran Tan Lip-Bu as its CEO and signalled the struggling but storied chipmaker was unlikely to split up its chip-design ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback